Key | % Net Assets |
---|---|
GlaxoSmithKline | 2.5% |
AstraZeneca | 2.4% |
Reynolds American | 2.1% |
Vodafone | 2.0% |
Other | 91% |
Name | % Net Assets |
---|---|
GlaxoSmithKline | 2.5% |
AstraZeneca | 2.4% |
Reynolds American | 2.1% |
Vodafone | 2.0% |
British American Tobacco | 2.0% |
BG | 2.0% |
Imperial Tobacco | 1.6% |
BP | 1.5% |
National Grid | 1.5% |
Tesco | 1.5% |
No asset data available.
Date | 21-Nov-2024 |
---|---|
NAV | 109.04p |
Currency | GBP |
Change | 0.11p |
% | 0.10% |
YTD change | 2.70p |
YTD % | 2.54% |
Fund Inception | 26/01/2004 |
---|---|
Fund Manager | Paul Causer / Paul Read / Neil Woodford |
TER | 1.07 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.04% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research